We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Diagnostic et gestion des effets secondaires pleuropulmonaires des inhibiteurs de tyrosine kinase Recommandations du Groupe français pour la leucémie myéloïde chronique.
- Authors
Berger, Marc; Charbonnier, Aude; Coiteux, Valérie; Cony-Makhoul, Pascale; EtiENne, Gabriel; Johnson-Ansah, Hyacinthe; Legros, LaurENce; Mahon, François-Xavier; Nicolini, Franck; Réa, Delphine; Rousselot, Philippe; Roy, Lydia; Bergeron, Anne; Laroumagne, Sophie; Montani, David; Risso, Karine
- Abstract
Pulmonary side effects are important adverse events of tyrosine kinase inhibitors (TKIs). Their prevention and treatment rely on their early recognition by trained hematologists and also on a close collaboration between pneumolo- gists and hematologists. Pleural effusions are most frequently seen and they are not life-threatening. Pulmonary symptoms reported by a patient treated with dasatinib and less frequently bosutinib are first evocative of pleural effusion. On the contrary, infrequent pulmonary events such as hypersensitivity pneumopathies or pulmonary hypertension (PH) must be recognized as soon as possible and are mainly observed with dasatinib. PH may engage the vital prognostic and if a diagnose of PH is suspected, then the patient has to be addressed to a specialized center in emergency. In some cases, pulmonary sides effects are combined together, emphasizing the fact that specialized diagnostic tools are mandatory. In most cases, the TKI has to be discontinued and in some well define situations may be resumed after complete recovery of the symptoms.
- Publication
Hematologie, 2018, Vol 24, Issue 2, p134
- ISSN
1264-7527
- Publication type
Article
- DOI
10.1684/hma.2018.1362